Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation

Introduction: Crizotinib is a kinase inhibitor targeting c-MET/ALK/ROS1 used as the first-line chemical for the treatment of non-small cell lung cancer (NSCLC) with ALK mutations. Although c-MET is frequently overexpressed in 35-72% of NSCLC, most NSCLCs are primarily resistant to crizotinib treatme...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Biol Sci
Asıl Yazarlar: Ding, Nan, You, Abin, Tian, Wei, Gu, Liankun, Deng, Dajun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ivyspring International Publisher 2020
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415423/
https://ncbi.nlm.nih.gov/pubmed/32792859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijbs.45886
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller